TMEM65

Across TCGA pan-cancer cohorts, TMEM65 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM65 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TMEM65 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM65 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where TMEM65 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.331	0.559	.007	12	view →
CCRCC	DFS	Quartile	III,IV	0.415	0.720	.028	8	view →
GBM	DFS	Tertile	All	0.824	0.586	.008	8	view →
LUAD	DFS	Tertile	All	0.423	0.837	.029	5	view →
LSCC	OS	Median	III,IV	0.459	0.834	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM65–PDAC (DFS)

Open the PDAC breakdown →